ZA200710813B - Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins - Google Patents

Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins

Info

Publication number
ZA200710813B
ZA200710813B ZA200710813A ZA200710813A ZA200710813B ZA 200710813 B ZA200710813 B ZA 200710813B ZA 200710813 A ZA200710813 A ZA 200710813A ZA 200710813 A ZA200710813 A ZA 200710813A ZA 200710813 B ZA200710813 B ZA 200710813B
Authority
ZA
South Africa
Prior art keywords
mpps
treating
prostate
modified pore
cells
Prior art date
Application number
ZA200710813A
Other languages
English (en)
Inventor
Buckley James Thomas
Original Assignee
Protox Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protox Therapeutics Inc filed Critical Protox Therapeutics Inc
Publication of ZA200710813B publication Critical patent/ZA200710813B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
ZA200710813A 2005-06-14 2007-12-12 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins ZA200710813B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69026905P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
ZA200710813B true ZA200710813B (en) 2008-10-29

Family

ID=37531919

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710813A ZA200710813B (en) 2005-06-14 2007-12-12 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins

Country Status (15)

Country Link
US (2) US8916161B2 (de)
EP (1) EP1891093B1 (de)
JP (1) JP5220594B2 (de)
KR (1) KR101365538B1 (de)
CN (1) CN101238145B (de)
AT (1) ATE502954T1 (de)
AU (1) AU2006257664B2 (de)
CA (1) CA2611839C (de)
DE (1) DE602006020867D1 (de)
DK (1) DK1891093T3 (de)
ES (1) ES2366380T3 (de)
IL (1) IL188143A (de)
NZ (1) NZ564954A (de)
WO (1) WO2006133553A1 (de)
ZA (1) ZA200710813B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502954T1 (de) 2005-06-14 2011-04-15 Protox Therapeutics Inc Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
CA2630559A1 (en) * 2005-11-21 2007-05-24 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
CA2657946A1 (en) * 2006-06-09 2007-12-13 Protox Therapeutics Incorporated Modified protein toxins targeting cytokine -receptor bearing cells and use thereof for treating disease
CN101688253A (zh) * 2007-07-12 2010-03-31 新泽西内科与牙科大学 抗毒素不稳定化技术
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
JP2012512183A (ja) 2008-12-15 2012-05-31 プロトックス セラピューティクス インコーポレイテッド 改変された孔形成性タンパク質プロアエロリシンを用いた前立腺炎の処置のための方法
US20140152801A1 (en) 2009-10-28 2014-06-05 Alentic Microscience Inc. Detecting and Using Light Representative of a Sample
US9041790B2 (en) 2009-10-28 2015-05-26 Alentic Microscience Inc. Microscopy imaging
US9075225B2 (en) 2009-10-28 2015-07-07 Alentic Microscience Inc. Microscopy imaging
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
AU2011316786A1 (en) * 2010-10-22 2013-05-02 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US20140044812A1 (en) * 2012-08-07 2014-02-13 Kuwait Institute For Scientific Research Anesthetic and therapeutic composition for use in aquaculture
US10502666B2 (en) * 2013-02-06 2019-12-10 Alentic Microscience Inc. Sample processing improvements for quantitative microscopy
WO2014205576A1 (en) 2013-06-26 2014-12-31 Alentic Microscience Inc. Sample processing improvements for microscopy
EP3456700A1 (de) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Markierte inhibitoren des prostataspezifischen membranantigens (psma), deren verwendung als kontrastmittel und pharmazeutika zur behandlung von prostatakrebs
CA2926183C (en) * 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3533473A3 (de) 2013-11-14 2019-12-18 Endocyte, Inc. Verbindungen für positronenemissionstomografie
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN110033449B (zh) * 2019-04-15 2023-06-27 苏州金唯智生物科技有限公司 电泳图的识别方法、装置、设备及存储介质
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
JP2022121814A (ja) * 2021-02-09 2022-08-22 国立大学法人神戸大学 藻類抑制剤

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5677274A (en) 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
WO1994025616A1 (en) 1993-04-28 1994-11-10 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US5777078A (en) 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (de) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatorische Oligonukleotide
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6066319A (en) 1996-04-30 2000-05-23 President And Fellows Of Harvard College Drug delivery using terminal complement components
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5798218A (en) 1996-09-24 1998-08-25 University Of British Columbia Innovation And Development Corporation Compositions and methods for the specific detection of thy-1 antigen
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP2001504334A (ja) 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6265540B1 (en) 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
US6545131B1 (en) 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
EP1003531B1 (de) 1997-05-20 2007-08-22 Ottawa Health Research Institute Verfahren zur Herstellung von Nukleinsäurekonstrukten
AU740597B2 (en) 1997-07-10 2001-11-08 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2299471C (en) 1997-08-15 2007-12-18 Cephalon Inc. Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
CA2318127A1 (en) 1998-01-20 1999-07-22 University Of Victoria Innovation And Development Corporation Detection of gpi anchored proteins
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
WO2000061613A2 (en) 1999-04-09 2000-10-19 The Johns Hopkins University Channel forming toxins as antiviral agents
US6179831B1 (en) * 1999-04-29 2001-01-30 Galil Medical Ltd. Method of cryoablating benign prostate hyperplasia
EP1052287A3 (de) 1999-05-10 2003-07-09 Transgene S.A. Komplex zur Übertragung von einem interessierenden anionischen Substanz auf einer Zelle
EP1052288A1 (de) 1999-05-10 2000-11-15 Transgene S.A. Komplex zur Ubertragung einer anionischen Substanz in einen Zell
WO2001009165A2 (en) 1999-07-29 2001-02-08 The Johns Hopkins University ACTIVATION OF PEPTIDE PRODRUGS BY hK2
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
US6200573B1 (en) * 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
AU2001259837A1 (en) 2000-05-09 2001-11-20 Greenville Hospital System Therapeutic pore-forming peptides
AU2001261474B2 (en) * 2000-05-15 2006-03-09 Celgene Corporation Compositions and methods for the treatment of cancer
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
FI116467B (fi) 2000-09-29 2005-11-30 Licentia Oy Uudet peptidiligandit
WO2002038799A2 (en) 2000-11-07 2002-05-16 University Of Victoria Innovation And Development Corporation Detection of proteases and screening for protease inhibitors
JP2004529676A (ja) * 2000-11-13 2004-09-30 ダブリュ アイ ティー アイ ピー コーポレーション 断熱領域を有する治療カテーテル
WO2002043773A2 (en) 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
US7456146B2 (en) 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
WO2003005889A2 (en) * 2001-07-10 2003-01-23 Ams Research Corporation Surgical kit for treating prostate tissue
JP4319908B2 (ja) * 2001-08-24 2009-08-26 ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法
WO2004060915A2 (en) * 2002-12-03 2004-07-22 Sloan-Kettering Institute For Cancer Research Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
CN100341569C (zh) * 2004-09-17 2007-10-10 温州三天制药有限公司 一种治疗前列腺增生症的复方蛋白酶药物及制备方法
ATE502954T1 (de) 2005-06-14 2011-04-15 Protox Therapeutics Inc Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine

Also Published As

Publication number Publication date
IL188143A0 (en) 2008-03-20
EP1891093B1 (de) 2011-03-23
CN101238145B (zh) 2013-04-24
ATE502954T1 (de) 2011-04-15
AU2006257664A1 (en) 2006-12-21
KR20080042067A (ko) 2008-05-14
ES2366380T3 (es) 2011-10-19
DK1891093T3 (da) 2011-07-11
KR101365538B1 (ko) 2014-02-21
US20100233191A1 (en) 2010-09-16
EP1891093A1 (de) 2008-02-27
US8916161B2 (en) 2014-12-23
IL188143A (en) 2012-10-31
WO2006133553A1 (en) 2006-12-21
AU2006257664B2 (en) 2013-01-10
CA2611839A1 (en) 2006-12-21
CN101238145A (zh) 2008-08-06
EP1891093A4 (de) 2008-10-01
JP2008546650A (ja) 2008-12-25
DE602006020867D1 (de) 2011-05-05
JP5220594B2 (ja) 2013-06-26
NZ564954A (en) 2011-02-25
US20160375095A1 (en) 2016-12-29
CA2611839C (en) 2016-02-02
US9950029B2 (en) 2018-04-24

Similar Documents

Publication Publication Date Title
ZA200710813B (en) Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
WO2012018404A3 (en) Use of her3 binding agents in prostate treatment
GB2434983A (en) Methods and compositions for wound healing
WO2005065418A3 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy
PL1902141T3 (pl) Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
MX2008007307A (es) Granulos/capsulas modificados que contienen ingrediente activo.
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
WO2007100675A3 (en) Collagenase for treating cellulite
WO2007095340A3 (en) Small-molecule modulators of trp-p8 activity
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
MX2008009579A (es) Metodo para el tratamiento de dolor neuropatico.
TNSN06059A1 (en) Use of polypeptides of the cupredoxin family in cancer therapy
WO2005020927A3 (en) Method of promoting graft survival with anti-tissue factor antibodies
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
WO2007081878A8 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
EP2386639A3 (de) Modifizierte porenformende Proteintoxine und Verwendung davon
WO2005060960A3 (en) Use of histamine to treat bone disease
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
DK1411971T3 (da) Anvendelse af lang gentraxin PTX3 til behandling af kvindelig sterilitet